Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intravenous N-Acetylcysteine for Acute Ischemic Stroke
NCT04918719Phase 2Completed
- Sponsor
- The Lundquist Institute
- Start
- Nov 2023
- Primary completion
- Sep 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in ischemic stroke comparing NAC arm with Placebo arm (2 arms). Primary endpoint: National Institutes of Health Stroke Scale at 90 days. Started Nov 2023; status: completed.
02
Drugs
acetylcysteine
03
Conditions
ischemic stroke
Beyond the preview
Go deeper on NCT04918719.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04918719.